Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
September 30 2024 - 1:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September
2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
30
September 2024 – “Divestment of NRT business outside US
complete”
|
99.1
Divestment of the nicotine replacement therapy business outside of
the US to Dr. Reddy's completed
30 September 2024: Haleon
plc ("Haleon") (LSE/NYSE: HLN) today announces that it has
completed the divestment of its nicotine replacement therapy
("NRT") business outside of the US.
On 26 June 2024, Haleon announced that it had entered into an
agreement to sell its NRT business outside of the US to Dr. Reddy's
Laboratories SA ("Dr. Reddy's"), a wholly owned subsidiary of Dr.
Reddy's Laboratories Limited for total consideration of up to
£500m (with additional proceeds from the transfer of
inventory), which comprises an upfront payment of £458m and
further deferred, performance-based consideration of up to
£42m payable during 2025 and H1 2026.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Sonya
Ghobrial
|
+44
7392 784784
|
Zoë Bird
|
+44
7736 746167
|
|
Rakesh
Patel
|
+44
7552 484646
|
Gemma
Thomas
|
+44 7985 175048
|
|
Emma
White
|
+44
7823 523562
|
|
|
|
Email: investor-relations@haleon.com
|
Email: corporate.media@haleon.com
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information please visit www.haleon.com
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
September 30, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Nov 2023 to Nov 2024
